
Shijie Xu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8062539/publications.pdf Version: 2024-02-01



SHILLE XIL

#	Article	IF	CITATIONS
1	Short-Term Instantaneous Prophylaxis and Efficient Treatment Against SARS-CoV-2 in hACE2 Mice Conferred by an Intranasal Nanobody (Nb22). Frontiers in Immunology, 2022, 13, 865401.	4.8	8
2	Infection of humanized mice with a novel phlebovirus presented pathogenic features of severe fever with thrombocytopenia syndrome. PLoS Pathogens, 2021, 17, e1009587.	4.7	16
3	AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer Journal, 2021, 11, 119.	6.2	46
4	A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration. Cell Reports, 2021, 37, 109869.	6.4	59
5	The induction and characterization of monoclonal antibodies specific to GP of Ebola virus. Journal of Medical Virology, 2020, 92, 996-1006.	5.0	1
6	Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy. Acta Biomaterialia, 2020, 109, 21-36.	8.3	34
7	A single-domain antibody inhibits SFTSV and mitigates virus-induced pathogenesis in vivo. JCI Insight, 2020, 5, .	5.0	27
8	PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells. International Journal of Nanomedicine, 2019, Volume 14, 17-32.	6.7	72
9	Extracellular vesicles expressing a single-chain variable fragment of an HIV-1 specific antibody selectively target Env ⁺ tissues. Theranostics, 2019, 9, 5657-5671.	10.0	38
10	Induction of neutralizing antibodies by human papillomavirus vaccine generated in mammalian cells. Antibody Therapeutics, 2019, 2, 45-53.	1.9	8
11	Herpes simplex virus type 2 infection triggers AP-1 transcription activity through TLR4 signaling in genital epithelial cells. Virology Journal, 2018, 15, 173.	3.4	18
12	Harmine, a small molecule derived from natural sources, inhibits enterovirus 71 replication by targeting NF-κB pathway. International Immunopharmacology, 2018, 60, 111-120.	3.8	31